Erratum: Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma (Cancer Gene Therapy (2005) 12 (381-388)) DOI: 10.1038/sj.cgt.7700789;Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma

Cancer Gene Therapy

Volumn 12, Issue 4, 2005, Pages 381-388

  Barzon, Luisa ^a   Gnatta, Elisa ^a   Castagliuolo, Ignazio ^a   Trevisan, Marta ^a   Moretti, Fabiola ^b   Pontecorvi, Alfredo ^c   Boscaro, Marco ^d   Palù, Giorgio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anaplastic thyroid carcinoma; Long terminal repeat; Retroviral vector; Thyroglobulin enhancer; TP53

Indexed keywords

GANCICLOVIR; INTERLEUKIN 2; PROTEIN P53; RETROVIRUS VECTOR; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; THYROTROPIN;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; GENE EXPRESSION; GENE REPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; TISSUE SPECIFICITY; WILD TYPE;

EID: 15744387391     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700859     Document Type: Erratum

References (26)

1. Barzon L, Pacenti M, Boscaro M, Pal̀u G. Gene therapy for thyroid cancer. Expert Opin Biol Ther. 2004;4:1225-1239.
2. Barzon L, Bonaguro R, Castagliuolo I, et al. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol. 2003;148:73-80.
3. Barzon L, Bonaguro R, Castagliuolo I, et al. Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer. J Clin Endocrinol Metab. 2002;87:5304-5311.
4. Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by Thyroid Transcription Factor-1 in thyroid cancer cells. Cancer Res. 2001;61:3640-3646.
5. Kitazono M, Chuman Y, Aikou T, Fojo T. Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway. Int J Cancer. 2002;99:453-459.
6. Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene. 1997;14: 729-740.
7. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 1993;91:179-184.
8. Ginsberg D, Michael-Michalovitz D, Ginsberg D, Oren M. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol. 1991; 11:582-585.
9. Palu G, Pizzato M, Bonaguro R, Colombo F. Gene therapy of glioblastoma multiforme with bicistronic retroviral vector expressing human IL-2 and HSV-TK. In: Walther W, Stein U, eds. Methods in Molecular Medicine, Vol 35: Gene Therapy: Methods and Protocols. Totowa, NJ: Humana Press, Inc.; 2000: 505-516.
10. Battista S, Martelli ML, Fedele M, et al. A mutated p53 gene alters thyroid cell differentiation. Oncogene. 1995; 11:2029-2037.
11. Casamassimi A, Miano MG, Porcellini A, et al. p53 genes mutated in the DNA binding site or at a specific COOH-terminal site exert divergent effects on thyroid cell growth and differentiation. Cancer Res. 1998;58: 2888-2894.
12. Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res. 1996;56:765-771.
13. Zeki K, Tanaka Y, Morimoto I, et al. Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. Int J Cancer. 1998;75:391-395.
14. Moretti F, Nanni S, Farsetti A, et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab. 2000;85:302-308.
15. Narimatsu M, Nagayama Y, Akino K, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab. 1998;83:3668-3672.
16. Imanishi R, Ohtsuru A, Iwamatsu M, et al. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab. 2002;87:4821-4824.
17. Kim SB, Ahn IM, Park HJ, et al. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck. 2001;23:223-229.
18. Nagayama Y, Yokoi H, Takeda K, et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab. 2000;85:4081-4086.
19. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 1991;5:151-159.
20. Deb S, Jackson CT, Subler MA, Martin DW. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol. 1992;66:6164-6170.
21. Subler MA, Martin DW, Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol. 1992;66:4757-4762.
22. Jackson P, Bos E, Braithwaite AW. Wild-type mouse p53 down-regulates transcription from different virus enhancer/ promoters. Oncogene. 1993;8:589-597.
23. Subler MA, Martin DW, Deb S. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol. 1994;68: 103-110.
24. Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun. 2000;279:383-390.
25. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA. 1991;88:9979-9983.
26. Berg V, Vassart G, Christophe D. Identification of a thyroid-specific and cAMP-responsive enhancer in the upstream sequences of the human thyroglobulin promoter. Biochim Biophys Acta. 1996;1307:35-38.